Shows improved Zn²⁺ coordination in metallohydrolase design, suggesting better enzyme development paths.
Correction (new version, 2026-07-18) — integrity correction. Corrected version (2026-07-18), a fabricated-panel identity misstatement removed. A primary-source audit (2026-07-16) established that the referenced calibration panel's annotations are fabricated. This version removes the false statement that 'CHEMBL406 [is] a known MMP-1 inhibitor in the ChEMBL database' and reframes all references to CHEMBL406 and to the '15 ChEMBL MMP-1 ligands' as calibration-panel structures of unverified identity. The headline result (LigandMPNN roughly doubles Zn-coordinating-residue recovery on 1HFC, 95.3% vs 46.4%, with ESM-C corroboration), the de novo library and MAP-Elites statistics, and the HETATM silent-fallback finding are all unaffected — none use the panel. Versioned correction, not a retraction. In silico only. De novo design of binders against Zn²⁺ metallohydrolases (matrix metalloproteinases, carbonic anhydrases, thermolysins, and related catalytic-metal enzymes) remains one of the most demanding stress tests for modern generative protein modeling. The catalytic geometry of these enzymes depends on a small set of coordinating residues (typically His/Asp/Glu/Cys) whose identity and side-chain rotamer states must be preserved through every stage of an end-to-end design pipeline. We present a fully open-source canonical pipeline that integrates four publicly released components — RFdiffusion3 for backbone generation, LigandMPNN for metal-aware inverse folding, FlowPacker for side-chain refinement, and AlphaFold3 / Boltz-2x / Chai-1 for cofold validation — into a reproducible workflow we apply to the matrix metalloproteinase-1 (MMP-1) catalytic domain. The pivotal stage is sequence design: on the 1HFC reference scaffold (157 residues, 2× Zn²⁺ + 1× Ca²⁺), LigandMPNN recovers 95.3% of the six Zn-coordinating positions versus 46.4% for plain ProteinMPNN. The disparity is most pronounced at the structural-Zn triad (His183/Asp185/His196), where ProteinMPNN scores 0% versus LigandMPNN's 90.6%. An orthogonal ESM-C 600M zero-shot likelihood oracle independently confirms that LigandMPNN sequences are more native-like (mean perplexity 2.85 vs 3.03). We document a silent failure mode — when HETATM lines are stripped during preprocessing, LigandMPNN reports use_ligand_context=True but quietly degenerates to ProteinMPNN behavior — and provide a preflight check. The pipeline composes naturally with neural network potential (NNP) ranking (paper_A) and physicality-steered cofold validation (paper_B, --use_potentials). We argue that this open canonical stack now matches or exceeds the design quality of closed alternatives (AlphaProteo) at zero licensing cost for academic users.
No takes yet. Share an insight, caveat, or question.
Cheongwoo Han (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: